Literature DB >> 18247126

Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes.

Marisela Agudelo1, Cathy Newton, Ray Widen, Tracy Sherwood, Liang Nong, Herman Friedman, Thomas W Klein.   

Abstract

Marijuana cannabinoid treatment increases Th2 activity, and previous reports showed that B cells express the highest level of CB(2) mRNA relative to other immune cells, suggesting that cannabinoids play a critical role in B cell activation and maturation. We previously reported evidence of Th2 biasing and class switching in cannabinoid-treated and antigen-challenged mice. We now explore the possibility that cannabinoids directly influence B cell antibody class switching. Mouse splenic B cells were purified by negative selection and cultured with IL4 and anti-CD40 in the presence or absence of the nonselective cannabinoid agonist, CP55940, or the CB(1) selective cannabinoid agonist, methanandamide, and analyzed at different days by flow cytometry for surface expression of either IgM or IgE. Cells treated with CP55940 showed an increase in expression of IgE by day 5 in culture; methanandamide had no effect. CP55940 also induced an increase in secreted IgE in culture supernatants as analyzed by ELISA. In addition, CB(2) receptors were increased on B cells after stimulation with IL-4 and anti-CD40, and the class switching effect of CP55940 was attenuated by the CB(2) antagonist, SR144528. These results suggest that cannabinoids bias toward Th2-type immunity by directly inducing B cell class switching from IgM to IgE through a mechanism involving CB(2) receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18247126      PMCID: PMC2423231          DOI: 10.1007/s11481-007-9088-9

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  16 in total

Review 1.  Regulation of interleukin-12 production by G-protein-coupled receptors.

Authors:  M C Braun; B L Kelsall
Journal:  Microbes Infect       Date:  2001-02       Impact factor: 2.700

2.  Cutting edge: STAT6 serves as a positive and negative regulator of gene expression in IL-4-stimulated B lymphocytes.

Authors:  Andreas J Schroder; Paul Pavlidis; Akinori Arimura; Danielle Capece; Paul B Rothman
Journal:  J Immunol       Date:  2002-02-01       Impact factor: 5.422

3.  Cross-linking surface Ig delays CD40 ligand- and IL-4-induced B cell Ig class switching and reveals evidence for independent regulation of B cell proliferation and differentiation.

Authors:  James S Rush; Jhagvaral Hasbold; Philip D Hodgkin
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

Review 4.  The cannabinoid system and immune modulation.

Authors:  Thomas W Klein; Cathy Newton; Kellie Larsen; Lily Lu; Izabella Perkins; Liang Nong; Herman Friedman
Journal:  J Leukoc Biol       Date:  2003-07-01       Impact factor: 4.962

5.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations.

Authors:  S Galiègue; S Mary; J Marchand; D Dussossoy; D Carrière; P Carayon; M Bouaboula; D Shire; G Le Fur; P Casellas
Journal:  Eur J Biochem       Date:  1995-08-15

6.  Prostaglandin E2 promotes B lymphocyte Ig isotype switching to IgE.

Authors:  R L Roper; D M Brown; R P Phipps
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

7.  Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism.

Authors:  N E Kaminski; W S Koh; K H Yang; M Lee; F K Kessler
Journal:  Biochem Pharmacol       Date:  1994-11-16       Impact factor: 5.858

8.  Essential role of Stat6 in IL-4 signalling.

Authors:  K Takeda; T Tanaka; W Shi; M Matsumoto; M Minami; S Kashiwamura; K Nakanishi; N Yoshida; T Kishimoto; S Akira
Journal:  Nature       Date:  1996-04-18       Impact factor: 49.962

9.  Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection.

Authors:  C A Newton; T W Klein; H Friedman
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

Review 10.  Cannabinoid-induced immune suppression and modulation of antigen-presenting cells.

Authors:  Thomas W Klein; Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 7.285

View more
  29 in total

1.  Alcohol Versus Cannabinoids: A Review of Their Opposite Neuro-Immunomodulatory Effects and Future Therapeutic Potentials.

Authors:  Madhavan P Nair; Gloria Figueroa; Gianna Casteleiro; Karla Muñoz; Marisela Agudelo
Journal:  J Alcohol Drug Depend       Date:  2015-01-23

Review 2.  Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease.

Authors:  Sreemanti Basu; Bonnie N Dittel
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

Review 3.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 4.  Endocannabinoid signalling in innate and adaptive immunity.

Authors:  Valerio Chiurchiù; Luca Battistini; Mauro Maccarrone
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

5.  Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.

Authors:  Jessica M Sido; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Leukoc Biol       Date:  2015-06-01       Impact factor: 4.962

6.  Genome-wide ancestry association testing identifies a common European variant on 6q14.1 as a risk factor for asthma in African American subjects.

Authors:  Dara G Torgerson; Daniel Capurso; Elizabeth J Ampleford; Xingnan Li; Wendy C Moore; Christopher R Gignoux; Donglei Hu; Celeste Eng; Rasika A Mathias; William W Busse; Mario Castro; Serpil C Erzurum; Anne M Fitzpatrick; Benjamin Gaston; Elliot Israel; Nizar N Jarjour; W Gerald Teague; Sally E Wenzel; José R Rodríguez-Santana; William Rodríguez-Cintrón; Pedro C Avila; Jean G Ford; Kathleen C Barnes; Esteban G Burchard; Timothy D Howard; Eugene R Bleecker; Deborah A Meyers; Nancy J Cox; Carole Ober; Dan L Nicolae
Journal:  J Allergy Clin Immunol       Date:  2012-05-18       Impact factor: 10.793

7.  Regulation of Cell Surface CB2 Receptor during Human B Cell Activation and Differentiation.

Authors:  Julie T Castaneda; Airi Harui; Michael D Roth
Journal:  J Neuroimmune Pharmacol       Date:  2017-03-31       Impact factor: 4.147

8.  Differential expression of intracellular and extracellular CB(2) cannabinoid receptor protein by human peripheral blood leukocytes.

Authors:  Julie T Castaneda; Airi Harui; Sylvia M Kiertscher; Jeffrey D Roth; Michael D Roth
Journal:  J Neuroimmune Pharmacol       Date:  2013-01-10       Impact factor: 4.147

9.  Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.

Authors:  Dario Siniscalco; Anna Sapone; Catia Giordano; Alessandra Cirillo; Laura de Magistris; Francesco Rossi; Alessio Fasano; James Jeffrey Bradstreet; Sabatino Maione; Nicola Antonucci
Journal:  J Autism Dev Disord       Date:  2013-11

10.  Suppression of T cell costimulator ICOS by Delta9-tetrahydrocannabinol.

Authors:  Haitian Lu; Barbara L F Kaplan; Thitirat Ngaotepprutaram; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2008-11-06       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.